Navigation Links
Sygnis Pharma AG announces date for presentation of clinical,results

HEIDELBERG, Germany, 11 July 2007 – On 23 July SYGNIS Pharma AG will present the results of the clinical phase IIa study for AX200 (AXIS-study).

AX200, a compound for the treatment of stroke, is the most advanced drug candidate in SYGNIS’ product pipeline. The primary aim of the study is to show safety and tolerability of AX200 in acute stroke patients. The results of the AXIS-study are expected to provide information for the further clinical development of AX200.

Furthermore, the company announces that this year’s Annual General Meeting will take place on 28 November 2007 in Eppelheim.

About SYGNIS Pharma

SYGNIS Pharma AG, with head offices in Heidelberg, is a specialist pharmaceutical company listed on the Prime Standard of the German stock exchange. The company is focusing on the research, development and marketing of innovative therapies for the treatment of neurodegenerative diseases. These include stroke, Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease or neurological disorders resulting from injury, such as trauma of the brain or spinal cord. All these disorders are characterised by the fact that, as the disease progresses, nerve cells die off. Although there is a great medical demand, there are currently no or only inadequate treatment options available.

In its drug development, the company has taken a completely novel approach: it develops compounds that protect nerve cells in the acute phase of the disease, and beyond that, also stimulate the regeneration of the damaged nervous system.

For more information, please contact:

Dr. Franz-Werner Haas Vice President Operations +49 (0) 6221 454 812 franz-werner.haas@sygnis.de

### Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as f orward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###


'"/>




Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , 11 de fevereiro de 2016  A ... sua fábrica de soroalbumina bovina (BSA -- ... fábrica fica na Ilha Norte da Nova Zelândia, ... e estabelecido na fábrica da Proliant nos EUA, ... O projeto e instalação dos equipamentos foram feitos ...
(Date:2/11/2016)... February 11, 2016 Breast Cancer Therapeutics ... Asia-Pacific (APAC) breast cancer market will ... billion by 2021, at a Compound Annual Growth Rate (CAGR) ... Markets to 2021 - states that the ... expansion from $1.9 billion in 2014 to $3.4 billion by ...
(Date:2/11/2016)... , February 11, 2016 ... at Worldwide Clinical Trials, will present at this year,s Summit ... the Hyatt Regency in Miami, FL. ... partnerships to optimize study execution, supporting SCOPE,s "Improving Site Study ... take place on Thursday, Feb. 25 at 11:05 a.m. ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... ... a master charity program created to assist the people of their local community. ... with nonprofit organizations and community leaders. Their hope is to bring awareness to ...
(Date:2/11/2016)... ... February 11, 2016 , ... Duterte Insurance Group, serving the ... a new charity campaign to raise funds for Ronald McDonald House Charities. On ... https://donate.rmhc.org/ . , Ronald McDonald House (RMH) is an internationally renowned nonprofit organization ...
(Date:2/11/2016)... VA (PRWEB) , ... February 11, 2016 , ... ... its new office in the heart of Old Town at 108 South Columbus St, ... and businesses the highest level of medical care in the convenience of their homes, ...
(Date:2/11/2016)... Denver, CO. (PRWEB) , ... February 11, 2016 ... ... American people have become more actively engaged in health and wellness best practices ... the importance of riding this trend. February is American Heart Month, which acts ...
(Date:2/10/2016)... ... 10, 2016 , ... President Obama’s budget proposal yesterday enables ... medical services via telehealth, estimated to generate more than $160 million in savings ... many years. Although there is more to be done, this represents an ...
Breaking Medicine News(10 mins):